Departing Leo Pharma executive plans to follow Genmab's example for new biotech: "It's a major aspiration, but it's can be done"
![Future Union Therapeutics CEO Kim Kjøller. | Foto: Leo Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12517579.ece/ALTERNATES/schema-16_9/doc7cyadagmn2seu1ql7iv.jpg)
Kim Kjøller's decision to leave the role of Executive Vice President Global Research&Development at Leo Pharma in favor of a CEO position in a minor biotech firm partly owes to his vision of creating a new frontrunner in the Danish pharmaceutical industry.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danish Covid-19 vaccine might be ready before 2021
For abonnenter